Alleviare India Logo

Genetic Named patient medicines and treatment

Manufacturing, approving and launching all the drugs is difficult especially for rare diseases. Patients suffering from rare diseases commonly suffer as they remain devoid of treatment. However, some pharmaceutical consulting services like AlleviareIndia provide services to the doctors, hospitals, patients and government hospitals with named patient medicines approved under named patient programs.

Genetic ailments fall under such rare ones that stay mostly untreated or exceptionally treated. However, by the succor of distribution of the required and FDA approved medicines, ‘AlleviareIndia’ supports treatment with the named patient supplies of the same.

Some such medicines are discussed below:

● Zavesca Miglustat – It is used to treat mild to moderate type 1 Gaucher disease. It        comes from both the parents and is generally found in those patients who lack an enzyme which is naturally found in the body and breaks a chemical known as Glucosylceramide. Thus, when the enzyme is not produced, glucosylceramide is not broken and causes spleen and liver enlargement, blood disease and bone disease. Zavesca Miglustat stops the body from producing of glycosylceramide, which minimizes the discomfort up to a greater extent.

● Elaprase Idursulfase – It treats Hunter syndrome which lacks an enzyme from the body and is usually replaced by Elaprase Idursulfase. The disease never supports any enzyme replacement therapy and is therefore not permanently curable.

 Cystagon – Required for the treatment of Nephrophatic Cystinosi. Cysteaine reduces cysteine accumulation in some cells and thus delays the development of renal failure.

 Cerdelga Miglustat – Like Zavesca Miglustat, Cerdelga serves the same purpose, but is prescribed for long-term treatment of adult patients suffering from Type 1 Gaucher disease.


AlleviareIndia extends services for facilitation of such genetic diseases, their medicines and treatment.

Advance medicinal treatment of Neurological disorder

Disorders occurring in the central and peripheral nervous system comprise of neurological disorders. These disorders include Alzheimer disease, dementias, cerebrovascular disease, Parkinson’s disease, and traumatic disorder. It is assessed that more than 6 million people die because of stroke each year and an astonishing figure of 80% is that from developing and poor countries.

Lack of proper medications and knowledge, in regards, to neurological disorder causes increasing mortality rate every year. Thus, FDA has approved some widely accepted drugs termed to be a named patient medicine, as the medicines are frequently not available in the underdeveloped and developing countries.

Xadago, an orally administered medicine for the patients suffering from Parkinson’s disease is recommended from 100 mg to 50 mg as per the condition of the patient. It inhibits MAO-B activity after hindering the catabolism of dopamine and thus acting as a mechanical obstruct for Parkinson disease.

Also, Banzel, a triazole derivative is an indicative treatment drug for Seizures allied with Lennox Gastaut syndrome, which is common among children above 4 years and then into adults. The prescribed initial dose per day ranges from 400 mg to 800 mg and a maximum dose of 3200 mg per day. Although the exact mechanism of Banzel is unknown, yet the rufinamide modulates the activity of sodium channels which, in turn, slows down the seizures and its aligned symptoms.

The pharmaceutical consulting services allow the neurology department and its named patient program to export these medicines worldwide, with all its approvals and advancement to cure the fatal diseases like Parkinson and Lennox Gastaut syndrome.